Logo image of AFMD

AFFIMED NV (AFMD) Stock Fundamental Analysis

NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock

1.14  -0.01 (-0.87%)

After market: 1.16 +0.02 (+1.75%)

Fundamental Rating

2

Overall AFMD gets a fundamental rating of 2 out of 10. We evaluated AFMD against 572 industry peers in the Biotechnology industry. AFMD may be in some trouble as it scores bad on both profitability and health. AFMD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AFMD had negative earnings in the past year.
In the past year AFMD has reported a negative cash flow from operations.
In the past 5 years AFMD always reported negative net income.
In the past 5 years AFMD always reported negative operating cash flow.
AFMD Yearly Net Income VS EBIT VS OCF VS FCFAFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

The Return On Assets of AFMD (-175.10%) is worse than 87.96% of its industry peers.
The Return On Equity of AFMD (-406.92%) is worse than 78.05% of its industry peers.
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROIC N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
AFMD Yearly ROA, ROE, ROICAFMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 789.74%, AFMD belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
AFMD's Gross Margin has declined in the last couple of years.
AFMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 789.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
AFMD Yearly Profit, Operating, Gross MarginsAFMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
AFMD has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, AFMD has more shares outstanding
The debt/assets ratio for AFMD is higher compared to a year ago.
AFMD Yearly Shares OutstandingAFMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AFMD Yearly Total Debt VS Total AssetsAFMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -3.97, we must say that AFMD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.97, AFMD is in line with its industry, outperforming 41.42% of the companies in the same industry.
AFMD has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.35, AFMD is doing worse than 72.92% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z -3.97
ROIC/WACCN/A
WACC8.08%
AFMD Yearly LT Debt VS Equity VS FCFAFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 1.93 indicates that AFMD should not have too much problems paying its short term obligations.
The Current ratio of AFMD (1.93) is worse than 76.99% of its industry peers.
AFMD has a Quick Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.93, AFMD is doing worse than 75.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
AFMD Yearly Current Assets VS Current LiabilitesAFMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.15% over the past year.
Looking at the last year, AFMD shows a very negative growth in Revenue. The Revenue has decreased by -95.39% in the last year.
Measured over the past years, AFMD shows a very negative growth in Revenue. The Revenue has been decreasing by -19.00% on average per year.
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%

3.2 Future

AFMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.90% yearly.
The Revenue is expected to grow by 41.19% on average over the next years. This is a very strong growth
EPS Next Y43.31%
EPS Next 2Y28.51%
EPS Next 3Y18.22%
EPS Next 5Y10.9%
Revenue Next Year-85.51%
Revenue Next 2Y-32.72%
Revenue Next 3Y2.16%
Revenue Next 5Y41.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AFMD Yearly Revenue VS EstimatesAFMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AFMD Yearly EPS VS EstimatesAFMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AFMD. In the last year negative earnings were reported.
Also next year AFMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFMD Price Earnings VS Forward Price EarningsAFMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFMD Per share dataAFMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

AFMD's earnings are expected to grow with 18.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.51%
EPS Next 3Y18.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AFMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AFFIMED NV

NASDAQ:AFMD (1/21/2025, 8:00:00 PM)

After market: 1.16 +0.02 (+1.75%)

1.14

-0.01 (-0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners34.83%
Inst Owner Change-0.02%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap17.36M
Analysts82.86
Price Target14.13 (1139.47%)
Short Float %5.19%
Short Ratio2.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.56%
Min EPS beat(2)-10.88%
Max EPS beat(2)1.75%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-10.88%
Max EPS beat(4)14.22%
EPS beat(8)4
Avg EPS beat(8)1.65%
EPS beat(12)7
Avg EPS beat(12)6.57%
EPS beat(16)8
Avg EPS beat(16)-11.38%
Revenue beat(2)0
Avg Revenue beat(2)-90.72%
Min Revenue beat(2)-92.4%
Max Revenue beat(2)-89.04%
Revenue beat(4)0
Avg Revenue beat(4)-85.87%
Min Revenue beat(4)-92.4%
Max Revenue beat(4)-74.24%
Revenue beat(8)2
Avg Revenue beat(8)-47.19%
Revenue beat(12)4
Avg Revenue beat(12)-23.39%
Revenue beat(16)7
Avg Revenue beat(16)-15.7%
PT rev (1m)-40.85%
PT rev (3m)-42.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.69%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)83.52%
Revenue NY rev (1m)-38.56%
Revenue NY rev (3m)-65.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.11
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.98
EV/EBITDA N/A
EPS(TTM)-4.73
EYN/A
EPS(NY)-2.54
Fwd EYN/A
FCF(TTM)-5.27
FCFYN/A
OCF(TTM)-5.23
OCFYN/A
SpS0.06
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 789.74%
FCFM N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 60.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -3.97
F-Score1
WACC8.08%
ROIC/WACCN/A
Cap/Depr(3y)175.27%
Cap/Depr(5y)145.6%
Cap/Sales(3y)18.76%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
EPS Next Y43.31%
EPS Next 2Y28.51%
EPS Next 3Y18.22%
EPS Next 5Y10.9%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%
Revenue Next Year-85.51%
Revenue Next 2Y-32.72%
Revenue Next 3Y2.16%
Revenue Next 5Y41.19%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.28%
OCF growth 3YN/A
OCF growth 5YN/A